News

The Next Steps in Psychedelic Health Treatment

The Emerald Magazine

June 22, 2022

Pharma-delics? UCSF Kicks Off First-Ever Trial of Drug Naturally Derived From Magic Mushrooms

San Francisco Standard

June 17, 2022

Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward

Benzinga

May 2, 2022

TDR’s Top 5 Psychedelic Developments For The Week Of April 25

The Dales Report

April 30, 2022

Filament Health Keeps Adding Patents To Its Portfolio, Just Received Its Fourth

Benzinga

April 27, 2022

News You Might Have Missed: April 19th, 2022

Microdose Buzz

April 19, 2022

Press Releases

Filament

Filament Health Announces Private Placement Of Units And Convertible Debenture Units Of Up To $2,500,000

June 30, 2022

Filament

Filament Health Announces Annual General Meeting Voting Results

June 28, 2022

Filament

Filament Health Announces Patient Dosing Through Health Canada Special Access Program

June 16, 2022

Filament

Filament Health Cultivates 70th Psychedelic Mushroom Variety And Announces Annual General Meeting

June 10, 2022

Filament

Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications

June 9, 2022

Filament

Filament Health is Issued Second Patent by United States Patent and Trademark Office and Reports Q1 Results

May 18, 2022

Filament

Filament Health Announces Fourth Patent Issuance

April 27, 2022

Filament

Filament Health and Psyence Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products

April 19, 2022

Filament

Filament Health is Issued Patent by United States Patent and Trademark Office

April 13, 2022

Filament

Filament Health Announces Pre-IND Meeting With United States Food and Drug Administration

April 12, 2022

Filament

Filament Health to Participate in Prominent Psychedelic Investor Conferences in April 2022

April 7, 2022

Filament

Filament Health Reports Q4 and Year End 2021 Financial Results and Operational Highlights

March 31, 2022

Filament

Filament Health Announces Second Patent Issuance

March 23, 2022

Filament

Filament Health to Participate in the 34th Annual Roth Conference

March 8, 2022

Filament

Filament Health and ATMA Journey Centers Announce Licensing Agreement

February 23, 2022

Filament

Filament Health and Cybin Therapeutics Announce Approval for Phase II Clinical Trial for Depression

January 31, 2022

Filament

Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers

January 26, 2022

Filament

Filament Health and Cybin Therapeutics Announce Licensing Agreement

January 14, 2022

Filament

Filament Health Recognizes the Restoration of Access to Restricted Drugs via the Health Canada Special Access Program

January 5, 2022

Filament

Filament Health Announces Health Canada Approval for Phase II Trial Administering New Psilocybin Microdose Formulation

January 4, 2022

Filament

Filament Health to Participate in Key Psychedelics Conferences in December 2021

December 1, 2021

Filament

Filament Health Announces Co-development and Exclusive Licensing Agreement with Entheotech Bioscience

November 18, 2021

Filament

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

November 15, 2021

Filament

Filament Health Announces FDA Authorization of Clinical Trial with First-ever Direct Psilocin Administration and First-ever Psychedelic Botanical Drug Candidates

November 2, 2021

Filament

Filament Health Announces DTC Eligibility and Up-list to the OTCQB Exchange

October 12, 2021

Filament

Filament Health Shares to Commence Trading on the OTC Market

September 7, 2021

Filament

Filament Health Files 20th Patent Application Including Three International PCT Applications

September 1, 2021

Filament

Filament Health Successfully Completes Industry-first Export of Natural GMP Psychedelics to the United States through its wholly owned subsidiary, Psilo Scientific Ltd.

August 26, 2021

Filament

Filament Health Announces Q2 2021 Financial Results

August 17, 2021

Filament

Filament Health Is the First Public Company to be Issued a Patent for Extraction of Natural Psilocybin

August 3, 2021

Filament

Regulatory Approvals Place Filament Health at the Forefront of Natural Psychedelic Research and Manufacturing

July 29, 2021

Filament

Filament Health to Host Virtual Investor Event

July 16, 2021

Filament

Filament Health Corp. Announces Approval for Listing on the Neo Exchange

June 22, 2021

Filament

Filament Announces Shareholder Approval of Amalgamation and Closing of Private Placement Financing

June 21, 2021

Filament

Filament Announces First GMP Batch of Pharmaceutical Grade Natural Psilocybin

June 11, 2021

Filament

Filament subsidiary, Psilo Scientific, Cultivates 20th Psychedelic Mushroom Variety and Provides Propagation Update

June 9, 2021

Filament

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to Advance First Drug Candidates Through FDA Phase 1 and Phase 2 Clinical Trials

June 1, 2021

Filament

Filament Announces C$10M Offering and Filing of Initial Listing Application

May 17, 2021

Events and Interviews

Psychedelic Diaries Podcast

CEO Ben Lightburn speaking at the PsyTechGlobal Conference about the value of natural psychedelics over synthetic.

PsyTechGlobal

CEO Ben Lightburn speaking at the PsyTechGlobal Conference about the value of natural psychedelics over synthetic.

TraderTV

CEO Ben Lightburn speaking at the PsyTechGlobal Conference about the value of natural psychedelics over synthetic.